ClinicalTrials.gg
CompletedNCT01569087Updated Dec 5, 2016Results posted

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

A Phase 2 interventional study of empegfilrastim and filgrastim in Chemotherapy-induced Neutropenia, sponsored by Biocad. Completed at 5 sites in Russian Federation. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-12-05.

Sponsored by Biocad · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing filgrastim in Neutropenia — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Neutropenia.

Enrollment
13th of 19
60 · median 130
Started
2012
the only one that year
Phase 2
11 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
2 of 21
Biocad

Among the 21 studies testing filgrastim in Neutropenia, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2012, is one of 11 in phase 2, and was the 13th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

1 of the 21 studies testing filgrastim in Neutropenia is open now. Recruiting first, the newest first:

About filgrastim

Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing filgrastim in Neutropenia, or all of them as a file.
02

Study summary

The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.

Read the detailed description

BCD-017-2 is an open-label randomized phase II clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia®) at a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy.

03

Conditions studied

  • Chemotherapy-induced Neutropenia

Keywords

  • empegfilgrastim
  • pegylated filgrastim
  • neutropenia
  • febrile neutropenia
  • chemotherapy-associated neutropenia
  • breast cancer
  • docetaxel
  • doxorubicin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form;
  • verified diagnosis of stage IIb/III/IV breast cancer;
  • Age of 18-70 years inclusive;
  • If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;
  • Performance Status of 0, 1 or 2, not increasing within during 2 weeks before randomization;
  • ANC level of 1500/μL and more at the beginning of the study
  • count of 100 000/μL and more at the beginning of the study
  • level of 90 g/l and more
  • Creatinine level \<1.5 mg/dl
  • Total level \<1.5 × the (ULN)
  • and/or AST levels \<2.5×ULN (5×ULN for patients with liver );
  • Alkaline phosphatase \<5×ULN;
  • >50% and more;
  • If the patient had received and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 500 mg/m2 for doxorubicin or 500 mg/m2 for epirubicin;
  • Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;
  • Patients of must implement reliable measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Patient has received two or more chemotherapy regimens for the breast cancer;
  • Documented to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its , PEGylated drugs, recombinant proteins.
  • Pregnancy or breastfeeding;
  • Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;
  • Concomitant radiotherapy (except selective radiotherapy of bone metastases);
  • Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;
  • History of bone marrow/stem cell transplantation;
  • Conditions limiting the patient's ability to follow the protocol;
  • grade 2/4 neuropathy
  • , , , T.Pallidum infection(s);
  • Acute or active chronic infections.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Empegfilgrastim 3 mg

    Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy

    Biological: empegfilrastim

  • Experimental
    Empegfilgrastim 6 mg

    Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy

    Biological: empegfilrastim

  • Active comparator
    Filgrastim

    Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy

    Biological: filgrastim

Interventions

  • Biologicalempegfilrastim

    Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.

    Also known as: Extimia, BCD-017, metpegfilgrastim, pegylated filgrastim, peg-GCSF, empegfilgrastim

  • Biologicalfilgrastim

    Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.

    Also known as: GCSF

06

What researchers measure

Primary outcomes

  1. CTCAE Grade 3/4 Neutropenia Incidence

    Time frame: 21 days

Secondary outcomes

  1. Mean Duration of CTCAE Grade 4 Neutropenia

    Time frame: 21 days

  2. The Duration of Any Grade Neutropenia

    Time frame: 21 days

  3. Low Level (Nadir) ANC x 10^9/L

    Time frame: 21 days

  4. Duration of Neutropenia From Nadir to ANC < 2,0 x 10^9 Cells/L on the First Cycle of Chemotherapy

    Time frame: 21 days

  5. Incidence of Febrile Neutropenia

    Time frame: 21 days

07

Results

Posted Oct 24, 2016

Participant flow

Participant flow — Overall Study
MilestoneEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
Started212019
Completed202018
Not completed101

Outcome measures

PrimaryCTCAE Grade 3/4 Neutropenia Incidence
Time frame:
21 days
Reported as:
Number · participants
CTCAE Grade 3/4 Neutropenia Incidence
participantsEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
CTCAE Grade 3/4 Neutropenia Incidence181311
Statistical analysis
  • Empegfilgrastim 3 mg vs Empegfilgrastim 6 mg vs Filgrastim · Fisher Exact · p = <0.05
SecondaryMean Duration of CTCAE Grade 4 Neutropenia
Time frame:
21 days
Reported as:
Mean · days
Mean Duration of CTCAE Grade 4 Neutropenia
daysEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
Mean Duration of CTCAE Grade 4 Neutropenia0.43 ± 0.500.40 ± 0.490.33 ± 0.47
SecondaryThe Duration of Any Grade Neutropenia
Time frame:
21 days
Reported as:
Mean · days
The Duration of Any Grade Neutropenia
daysEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
The Duration of Any Grade Neutropenia1.86 ± 1.391.0 ± 0.790.78 ± 0.43
SecondaryLow Level (Nadir) ANC x 10^9/L
Time frame:
21 days
Reported as:
Median · cells x 10^9/L
Low Level (Nadir) ANC x 10^9/L
cells x 10^9/LEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
Low Level (Nadir) ANC x 10^9/L0.57 (0.3 to 0.73)0.75 (0.28 to 1.32)0.82 (0.4 to 1.89)
SecondaryDuration of Neutropenia From Nadir to ANC < 2,0 x 10^9 Cells/L on the First Cycle of Chemotherapy
Time frame:
21 days
Reported as:
Mean · days
Duration of Neutropenia From Nadir to ANC < 2,0 x 10^9 Cells/L on the First Cycle of Chemotherapy
daysEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
Duration of Neutropenia From Nadir to ANC < 2,0 x 10^9 Cells/L on the First Cycle of Chemotherapy4.8 ± 1.643.8 ± 2.043.00 ± 1.71
SecondaryIncidence of Febrile Neutropenia
Time frame:
21 days
Reported as:
Number · participants
Incidence of Febrile Neutropenia
participantsEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
Incidence of Febrile Neutropenia110

Adverse events

Collected over 1 month. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empegfilgrastim 3 mg—0/21 (0%)21/21 (100%)
Empegfilgrastim 6 mg—0/20 (0%)20/20 (100%)
Filgrastim—2/19 (10.5%)19/19 (100%)
Most frequent serious events
Most frequent serious events
EventEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
neutropenia grade 4Blood and lymphatic system disorders0/210/202/19
Most frequent other events
Showing 10 of 15
Most frequent other events
EventEmpegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastim
white blood cells decreasedBlood and lymphatic system disorders21/2119/2017/19
hiperglicemiaEndocrine disorders15/2116/2016/19
anemiaBlood and lymphatic system disorders12/2112/2015/19
alopeciaGeneral disorders8/2111/2012/19
TrombocitopeniaBlood and lymphatic system disorders11/2112/206/19
neutropenia grade 4Blood and lymphatic system disorders9/219/207/19
neutropenia grade 3Blood and lymphatic system disorders9/216/206/19
fatigueGeneral disorders7/218/207/19
ALT decreasedHepatobiliary disorders8/216/205/19
nouseaGeneral disorders3/217/205/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
<=18 years0000
Between 18 and 65 years21201960
>=65 years0000
Age, Continuous
Age, Continuous(years)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
Median54.0 (45.9 to 58.8)53.5 (48.6 to 57.7)48.7 (46.3 to 54.8)53.5 (46.5 to 57.1)
Gender
Gender(Participants)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
Female21201960
Male0000
Region of Enrollment
Region of Enrollment(participants)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
Russian Federation21201960
Duration of a disease
Duration of a disease(months)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
Median0.8 (0.4 to 5.8)0.6 (0.3 to 2.5)0.5 (0.2 to 1.0)0.65 (0.33 to 1.58)
Histologic type of a breast cancer
Histologic type of a breast cancer(participants)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
ductal15111541
lobular0303
ductal/lobular1001
medullar2002
no data36413
Expression of hormone receptors
Expression of hormone receptors(participants)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
estrogen receptors4026
estrogen and progesterone receptors710724
deficiency estrogen and progesterone receptors99927
no data1113
HER2 expression
HER2 expression(participants)Empegfilgrastim 3 mgEmpegfilgrastim 6 mgFilgrastimTotal
1+63312
2+34310
3+63817
deficiency HER2 expression59519
no data1102

1 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • Arkhangelsk District Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • Perm Region Oncology Dispensary
    Perm, 614066, Russian Federation
  • N.N.Petrov Oncology Research Center
    St.Petersburg, 197758, Russian Federation
  • Russian scientific center of radiology and surgery technologies
    St.Petersburg, Russian Federation
  • Volgograd District Oncology Dispensary №1
    Volgograd, 400138, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jan 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2012
First posted
Apr 2, 2012
Start
May 2012
Primary completionActual
Jan 2013
CompletionActual
Feb 2013
Results first posted
Oct 24, 2016
Last update
Dec 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01569087
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
May 2012
Primary completion
Jan 2013
Completion
Feb 2013
Results posted
Oct 24, 2016
Last update
Dec 5, 2016

Study contacts

Roman A. Ivanov, MD, PhD
study director · Biocad

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion